XOMA (NASDAQ:XOMA) Research Coverage Started at SVB Leerink

SVB Leerink assumed coverage on shares of XOMA (NASDAQ:XOMA) in a research note published on Monday, Marketbeat.com reports. The firm issued an outperform rating and a $40.00 target price on the biotechnology company’s stock.

Separately, HC Wainwright reissued a buy rating and issued a $74.00 price objective on shares of XOMA in a report on Thursday, April 25th.

XOMA Trading Up 1.9 %

Shares of NASDAQ XOMA opened at $25.82 on Monday. The company has a quick ratio of 8.68, a current ratio of 8.68 and a debt-to-equity ratio of 1.34. The stock’s 50 day moving average price is $25.06 and its two-hundred day moving average price is $20.68. The stock has a market capitalization of $300.42 million, a P/E ratio of -6.39 and a beta of 0.58. XOMA has a 52-week low of $13.48 and a 52-week high of $27.00.

XOMA (NASDAQ:XOMA) last announced its quarterly earnings results on Friday, March 8th. The biotechnology company reported ($0.49) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.36) by ($0.13). The company had revenue of $1.83 million for the quarter, compared to analyst estimates of $1.01 million. XOMA had a negative return on equity of 25.17% and a negative net margin of 886.91%. On average, analysts anticipate that XOMA will post -1.73 earnings per share for the current fiscal year.

Institutional Investors Weigh In On XOMA

A hedge fund recently raised its stake in XOMA stock. Stonepine Capital Management LLC lifted its stake in shares of XOMA Co. (NASDAQ:XOMA) by 25.0% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 436,602 shares of the biotechnology company’s stock after acquiring an additional 87,203 shares during the quarter. XOMA accounts for 2.0% of Stonepine Capital Management LLC’s portfolio, making the stock its 12th largest holding. Stonepine Capital Management LLC owned 3.80% of XOMA worth $6,152,000 as of its most recent filing with the Securities & Exchange Commission. Institutional investors own 95.92% of the company’s stock.

About XOMA

XOMA Corporation operates as a biotech royalty aggregator in the United States and the Asia Pacific. It has a portfolio of economic rights to future potential milestone and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The company also focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners; and acquires milestone and royalty revenue streams on late-stage clinical or commercial assets.